Immatics (IMTX)
(Delayed Data from NSDQ)
$11.49 USD
+0.28 (2.50%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $11.49 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
IMTX 11.49 +0.28(2.50%)
Will IMTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMTX
AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
IMTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Invest in BioMarin (BMRN) Stock Now
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates
Other News for IMTX
IMTX Makes Notable Cross Below Critical Moving Average
Buy Rating for Immatics: Promising Clinical Trials and Strong Financials Signal Upside Potential
Buy Rating Justified by Immatics’ Advancing Pipeline and Strategic Financial Position
Buy Rating Affirmed on Immatics’ Promising Pipeline and Upcoming Data Catalysts
IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q2 2024